Associated Papers
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
40503459 (PubMed )
Supplement: mmc1.xlsx › Supplementary_Table_S2
Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.
Nishiyama A et al.
Cancer Science, 2025
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
25425582 (PubMed )
Supplement: supp_ERC-14-0491_Supplementary_table_2.xlsx › Sheet1
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L et al.
Journal of Internal Medicine, 2009
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z et al.
Oncogene, 2009
Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Dvorakova S et al.
Molecular and Cellular Endocrinology, 2008
New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma.
Dvoráková S et al.
Thyroid : Official Journal of the American Thyroid Association, 2006
Select a paper to view details